Systematic Review on Advances and Challenges in Chemotherapy of the Patient - Medical Science Assignment Help

Assignment Task:

Task:

Systematic review on Advances and Challenges in Chemotherapy of the Patient with Pancreatic Cancer using FOLFIRINOX
Introduction
Pancreas is an organ involved in digestion. Pancreas releases enzymes that are required for digestion and is responsible for producing insulin to control blood sugar levels. Pancreas is located behind the stomach in the front of spine, It is about 15 cm long and 5 cm wide. (Zhu, H. et al. 2018)

Epidemiology
Pancreatic cancer (PC) is about 95% of the tumours that arise in the pancreas. The most common type of pancreatic tumour is ductal adenocarcinoma (PDAC). It accounts for about 85% of all neoplasms and more than 95% of all PCs arise from the exocrine (digestive enzymes) elements. PDAC is one of the largest causes of cancer-related mortality in the Western world. Incidence rates are increasing rapidly, with majority of patients being metastatic at diagnosis and progression within 1 year of diagnosis. (Kindler, H.L, et al. 2012) Prognosis of PDAC remains poor with a 5-year survival rate of 8%. The only potential cure is surgical resection. However, only about 10-15% of patients that have PC are eligible, as at diagnosis 52% of PC cases are stage IV (metastatic). Stage IV patients are eligible for chemotherapy regimens with the aim to prolong survival and reduce symptoms, mainly by increasing quality of life. Lifetime risk of developing pancreatic cancer (PC) is about 1.5%. PC affects both males and females almost equally. The average age of the patients that develop PC is about 70 years.

Methods
This systematic review was conducted according to the Preferred Reporting items for systematic reviews and Meta-Analysis (PRISMA) guidelines.
Search and selection
Data bases such as PubMed, Web of Science, Nature, and Scopus were systematically searched for full text studies published from 2010 to 2021. The main keywords used are: Pancreatic cancer and cytotoxic drugs OR Pancreatic cancer and phase III trial. FOLFIRINOX and Pancreatic cancer. FOLFIRINOX vs Gemcitabine and Pancreatic cancer, dose modified FOLFIRINOX, Adenocarcinoma AND FOLFIRINOX. Adjuvant therapy AND Pancreatic cancer.

This Medical Science Assignment has been solved by our Medical Science Experts at My Uni Paper. Our Assignment Writing Experts are efficient to provide a fresh solution to this question. We are serving more than 10000+ Students in Australia, UK & US by helping them to score HD in their academics. Our Experts are well trained to follow all marking rubrics & referencing style.

Be it a used or new solution, the quality of the work submitted by our assignment experts remains unhampered. You may continue to expect the same or even better quality with the used and new assignment solution files respectively. There’s one thing to be noticed that you could choose one between the two and acquire an HD either way. You could choose a new assignment solution file to get yourself an exclusive, plagiarism (with free Turnitin file), expert quality assignment or order an old solution file that was considered worthy of the highest distinction.